CERo Therapeutics Holdings Inc (NASDAQ: CERO)’s stock price has dropped by -9.63 in relation to previous closing price of 0.08. Nevertheless, the company has seen a loss of -0.92% in its stock price over the last five trading days. globenewswire.com reported 2024-10-21 that Company announces submission of IND Clinical Hold Complete Response Letter SOUTH SAN FRANCISCO, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, provides the following corporate update to stockholders from Interim CEO Chris Ehrlich.
Is It Worth Investing in CERo Therapeutics Holdings Inc (NASDAQ: CERO) Right Now?
CERO has 36-month beta value of -0.47.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CERO is 40.96M, and currently, short sellers hold a 1.08% ratio of that float. The average trading volume of CERO on November 05, 2024 was 8.70M shares.
CERO’s Market Performance
CERO stock saw a decrease of -0.92% in the past week, with a monthly decline of -19.42% and a quarterly a decrease of -46.66%. The volatility ratio for the week is 9.68%, and the volatility levels for the last 30 days are 10.68% for CERo Therapeutics Holdings Inc (CERO). The simple moving average for the past 20 days is -14.52% for CERO’s stock, with a -95.54% simple moving average for the past 200 days.
CERO Trading at -22.90% from the 50-Day Moving Average
After a stumble in the market that brought CERO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -99.41% of loss for the given period.
Volatility was left at 10.68%, however, over the last 30 days, the volatility rate increased by 9.68%, as shares sank -19.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.05% lower at present.
During the last 5 trading sessions, CERO fell by -0.92%, which changed the moving average for the period of 200-days by -99.32% in comparison to the 20-day moving average, which settled at $0.0879. In addition, CERo Therapeutics Holdings Inc saw -99.32% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CERO
The total capital return value is set at -13.35. Equity return is now at value -4090.08, with -45.32 for asset returns.
Based on CERo Therapeutics Holdings Inc (CERO), the company’s capital structure generated 1.15 points at debt to capital in total, while cash flow to debt ratio is standing at -4.22. The debt to equity ratio resting at -7.49. The interest coverage ratio of the stock is -394.63.
Currently, EBITDA for the company is 491.57 with net debt to EBITDA at 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.48.
Conclusion
To put it simply, CERo Therapeutics Holdings Inc (CERO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
